Systemic Inflammatory Markers Are Predictive of the Response to Brachytherapy in the Prostate.
inflammation
neutrophil to lymphocyte ratio
platelet to lymphocyte ratio
prostate cancer
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
23 09 2020
23 09 2020
Historique:
received:
15
07
2020
revised:
21
09
2020
accepted:
22
09
2020
entrez:
26
9
2020
pubmed:
27
9
2020
medline:
14
5
2021
Statut:
epublish
Résumé
We analyzed the influence of the neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) on the biochemical recurrence (BCR) in low-intermediate risk prostate cancer (PCa). A total of 604 patients treated with exclusive brachytherapy for low- and intermediate-risk cancers were included in this study. No patient received either androgen deprivation or brachytherapy as a boost. BCR was defined according to the Phoenix definition (nadir prostatic specific antigen (PSA) +2). The median follow-up was 60 months (IQR 44-48 months). An NLR > 3 was more frequent in statin users (
Identifiants
pubmed: 32977662
pii: cells9102153
doi: 10.3390/cells9102153
pmc: PMC7598188
pii:
doi:
Substances chimiques
Androgen Antagonists
0
KLK3 protein, human
EC 3.4.21.-
Kallikreins
EC 3.4.21.-
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
J Natl Cancer Inst. 2014 May 29;106(6):dju124
pubmed: 24875653
Int J Clin Pract. 2007 Mar;61(3):425-30
pubmed: 17313610
World J Urol. 2015 Jan;33(1):93-7
pubmed: 24671610
J Clin Oncol. 2010 Jun 1;28(16):2653-9
pubmed: 20421534
PLoS One. 2016 Apr 20;11(4):e0153981
pubmed: 27096158
Oncologist. 2012;17(12):1508-14
pubmed: 22971522
Otolaryngol Head Neck Surg. 2018 Apr;158(4):667-676
pubmed: 29359615
Cancer Immunol Immunother. 2020 Apr;69(4):559-568
pubmed: 31974724
Cancer Res. 2010 Jul 15;70(14):5679-85
pubmed: 20631066
Can J Urol. 2018 Oct;25(5):9509-9515
pubmed: 30281009
BJU Int. 2014 Jun;113(6):986-92
pubmed: 24053309
Nat Rev Cancer. 2007 Apr;7(4):256-69
pubmed: 17384581
BJU Int. 2013 Oct;112(6):735-41
pubmed: 23746332
BMC Cancer. 2015 Aug 21;15:594
pubmed: 26292807
Int J Radiat Oncol Biol Phys. 2016 Sep 1;96(1):170-8
pubmed: 27511854
J Inflamm (Lond). 2016 Nov 25;13:35
pubmed: 27924136
Clin Genitourin Cancer. 2016 Feb;14(1):e1-8
pubmed: 26341038
World J Urol. 2015 Nov;33(11):1661-7
pubmed: 25617235
Target Oncol. 2017 Oct;12(5):695-701
pubmed: 28712059
Prostate Cancer Prostatic Dis. 2015 Mar;18(1):63-8
pubmed: 25403419
Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1204-12
pubmed: 24793958
Cancer. 2015 Feb 15;121(4):545-55
pubmed: 25336438
Int J Cancer. 2016 Feb 1;138(3):671-8
pubmed: 26270488
Crit Rev Oncol Hematol. 2013 Oct;88(1):218-30
pubmed: 23602134
Diabetes Obes Metab. 2014 Feb;16(2):97-110
pubmed: 23668396
Ann Surg Oncol. 2018 Oct;25(11):3341-3349
pubmed: 30066226